Ovarian cancer is a highly lethal neoplasm due to its ability to form tumor implants on the peritoneal mesothelial surface of the abdominal cavity and bowel serosa. The mechanism by which ovarian cancer cells bind to peritoneal mesothelium most likely involves cell-cell recognition through specific adhesion molecules. In order to study this phenomenon, we have developed methods to isolate normal and malignant ovarian epithelial cells and have used an in vitro adhesion assay to quantitate the binding of these cells to peritoneal mesothelium. We have determined that the CD44 adhesion molecule is partly responsible for ovarian cancer cell binding through recognition of mesothelial-associated hyaluronate, a known ligand for CD44. In addition, we have found that ovarian cancer cells also bind through a CD44-independent mechanism which is not related to known adhesion proteins such as integrins or selectins. The first specific aim of this proposal is to determine the in vivo relevance of CD44 in the process of ovarian cancer cell implantation. By using a well-established nude mouse model, we will determine the effects of interfering with CD44 function (with neutralizing antibody or with soluble CD44 protein) on the implantation of CD44-positive ovarian cancer cells in vivo. We will also use a CD44-negative, implantation- incompetent ovarian cancer cell line to determine the effects of CD44 expression (by transfection) on in vivo implantation. In the second specific aim, the regulation of CD44 expression and function will be investigated in normal and malignant ovarian epithelial cells at the gene level using Southern and Northern analyses, and at the protein level using pulse-chase techniques. The third specific aim is to identify additional adhesion molecules which mediate the CD44-independent binding of ovarian cancer cells to peritoneal mesothelium. By using either ovarian cancer cells or mesothelial cells as immunogens, monoclonal antibodies will be generated and screened for their ability to neutralize binding. These neutralizing antibodies will provide useful tools for identifying potentially novel adhesion molecules expressed by either malignant ovarian epithelium or by peritoneal mesothelial cells. These studies should lead to a better understanding of the role of adhesion molecules in the process of ovarian cancer cell implantation. A complete characterization of these structures may eventually permit the design of adhesion antagonists capable of interfering with or reversing the intraabdominal spread of ovarian cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA060670-03
Application #
2101422
Study Section
Special Emphasis Panel (SRC (50))
Project Start
1993-08-01
Project End
1997-05-31
Budget Start
1995-06-01
Budget End
1996-05-31
Support Year
3
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
149617367
City
Boston
State
MA
Country
United States
Zip Code
02215
Strobel, T; Tai, Y T; Korsmeyer, S et al. (1998) BAD partly reverses paclitaxel resistance in human ovarian cancer cells. Oncogene 17:2419-27
Tai, Y T; Lee, S; Niloff, E et al. (1998) BAX protein expression and clinical outcome in epithelial ovarian cancer. J Clin Oncol 16:2583-90
Strobel, T; Swanson, L; Korsmeyer, S et al. (1997) Radiation-induced apoptosis is not enhanced by expression of either p53 or BAX in SW626 ovarian cancer cells. Oncogene 14:2753-8
Strobel, T; Swanson, L; Cannistra, S A (1997) In vivo inhibition of CD44 limits intra-abdominal spread of a human ovarian cancer xenograft in nude mice: a novel role for CD44 in the process of peritoneal implantation. Cancer Res 57:1228-32
Ottensmeier, C; Swanson, L; Strobel, T et al. (1996) Absence of constitutive EGF receptor activation in ovarian cancer cell lines. Br J Cancer 74:446-52
Strobel, T; Swanson, L; Korsmeyer, S et al. (1996) BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway. Proc Natl Acad Sci U S A 93:14094-9
Cannistra, S A; DeFranzo, B; Niloff, J et al. (1995) Functional heterogeneity of CD44 molecules in ovarian cancer cell lines. Clin Cancer Res 1:333-42
Cannistra, S A; Ottensmeier, C; Niloff, J et al. (1995) Expression and function of beta 1 and alpha v beta 3 integrins in ovarian cancer. Gynecol Oncol 58:216-25
Cannistra, S A; Abu-Jawdeh, G; Niloff, J et al. (1995) CD44 variant expression is a common feature of epithelial ovarian cancer: lack of association with standard prognostic factors. J Clin Oncol 13:1912-21
Cannistra, S A; Ottensmeier, C; Tidy, J et al. (1994) Vascular cell adhesion molecule-1 expressed by peritoneal mesothelium partly mediates the binding of activated human T lymphocytes. Exp Hematol 22:996-1002

Showing the most recent 10 out of 11 publications